163 related articles for article (PubMed ID: 38393723)
21. [Diagnosis and treatment of pancreatic neuroendocrine neoplasmas in Von Hippel-Lindau syndrome].
Liu WK; Tian XD; Yang YM
Zhonghua Wai Ke Za Zhi; 2018 Nov; 56(11):869-872. PubMed ID: 30392308
[TBL] [Abstract][Full Text] [Related]
22. Epidemiology and economic burden of Von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States.
Jonasch E; Song Y; Freimark J; Berman R; Nguyen H; Signorovitch J; Sundaram M
Orphanet J Rare Dis; 2024 Feb; 19(1):73. PubMed ID: 38365728
[TBL] [Abstract][Full Text] [Related]
23.
Satoh K; Sadowski SM; Dieckmann W; Quezado M; Nilubol N; Kebebew E; Patel D
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):714-721. PubMed ID: 27638678
[TBL] [Abstract][Full Text] [Related]
24. Neurological applications of belzutifan in von Hippel-Lindau disease.
Zhang Y; Nguyen CC; Zhang NT; Fink NS; John JD; Venkatesh OG; Roe JD; Hoffman SC; Lesniak MS; Wolinsky JP; Horbinski C; Szymaniak BM; Buerki RA; Sosman JA; Shenoy NK; Lukas RV
Neuro Oncol; 2023 May; 25(5):827-838. PubMed ID: 36215167
[TBL] [Abstract][Full Text] [Related]
25. Pancreatic involvement in Von Hippel-Lindau disease.
Eras M; Yenigun M; Acar C; Kumbasar B; Sar F; Bilge T
Indian J Cancer; 2004; 41(4):159-61. PubMed ID: 15659868
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis and management of pancreatic neuroendocrine tumor in von Hippel-Lindau disease.
Tamura K; Nishimori I; Ito T; Yamasaki I; Igarashi H; Shuin T
World J Gastroenterol; 2010 Sep; 16(36):4515-8. PubMed ID: 20857520
[TBL] [Abstract][Full Text] [Related]
27. Association of VHL Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippel-Lindau Disease.
Tirosh A; Sadowski SM; Linehan WM; Libutti SK; Patel D; Nilubol N; Kebebew E
JAMA Oncol; 2018 Jan; 4(1):124-126. PubMed ID: 29075773
[TBL] [Abstract][Full Text] [Related]
28. De novo VHL germline mutation detected in a patient with mild clinical phenotype of von Hippel-Lindau disease.
Ding X; Zhang C; Frerich JM; Germanwala A; Yang C; Lonser RR; Mao Y; Zhuang Z; Zhang M
J Neurosurg; 2014 Aug; 121(2):384-386. PubMed ID: 24678776
[TBL] [Abstract][Full Text] [Related]
29. [Pancreatic neuroendocrine tumors and von Hippel-Lindau disease].
Musso C; Paraf F; Petit B; Archambeaud-Mouveroux F; Valleix D; Labrousse F
Ann Pathol; 2000 Mar; 20(2):130-3. PubMed ID: 10740008
[TBL] [Abstract][Full Text] [Related]
30. MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.
Hasanov E; Jonasch E
Expert Opin Investig Drugs; 2021 May; 30(5):495-504. PubMed ID: 33945366
[TBL] [Abstract][Full Text] [Related]
31. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs).
Blansfield JA; Choyke L; Morita SY; Choyke PL; Pingpank JF; Alexander HR; Seidel G; Shutack Y; Yuldasheva N; Eugeni M; Bartlett DL; Glenn GM; Middelton L; Linehan WM; Libutti SK
Surgery; 2007 Dec; 142(6):814-8; discussion 818.e1-2. PubMed ID: 18063061
[TBL] [Abstract][Full Text] [Related]
32. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.
Roma A; Maruzzo M; Basso U; Brunello A; Zamarchi R; Bezzon E; Pomerri F; Zovato S; Opocher G; Zagonel V
Fam Cancer; 2015 Jun; 14(2):309-16. PubMed ID: 25391617
[TBL] [Abstract][Full Text] [Related]
33. Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.
Weisbrod AB; Zhang L; Jain M; Barak S; Quezado MM; Kebebew E
Horm Cancer; 2013 Jun; 4(3):165-75. PubMed ID: 23361940
[TBL] [Abstract][Full Text] [Related]
34. Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors.
Krauss T; Ferrara AM; Links TP; Wellner U; Bancos I; Kvachenyuk A; Villar Gómez de Las Heras K; Yukina MY; Petrov R; Bullivant G; von Duecker L; Jadhav S; Ploeckinger U; Welin S; Schalin-Jäntti C; Gimm O; Pfeifer M; Ngeow J; Hasse-Lazar K; Sansó G; Qi X; Ugurlu MU; Diaz RE; Wohllk N; Peczkowska M; Aberle J; Lourenço DM; Pereira MAA; Fragoso MCBV; Hoff AO; Almeida MQ; Violante AHD; Quidute ARP; Zhang Z; Recasens M; Díaz LR; Kunavisarut T; Wannachalee T; Sirinvaravong S; Jonasch E; Grozinsky-Glasberg S; Fraenkel M; Beltsevich D; Egorov VI; Bausch D; Schott M; Tiling N; Pennelli G; Zschiedrich S; Därr R; Ruf J; Denecke T; Link KH; Zovato S; von Dobschuetz E; Yaremchuk S; Amthauer H; Makay Ö; Patocs A; Walz MK; Huber TB; Seufert J; Hellman P; Kim RH; Kuchinskaya E; Schiavi F; Malinoc A; Reisch N; Jarzab B; Barontini M; Januszewicz A; Shah N; Young WF; Opocher G; Eng C; Neumann HPH; Bausch B
Endocr Relat Cancer; 2018 Sep; 25(9):783-793. PubMed ID: 29748190
[TBL] [Abstract][Full Text] [Related]
35. Germline VHL gene variant in patients with von Hippel-Lindau disease does not predict renal tumor growth.
Farhadi F; Nikpanah M; Li X; Symons R; Pourmorteza A; Merino MJ; Linehan WM; Malayeri AA
Abdom Radiol (NY); 2018 Oct; 43(10):2743-2749. PubMed ID: 29525880
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic lesions in von Hippel-Lindau disease? A systematic review and meta-synthesis of the literature.
Charlesworth M; Verbeke CS; Falk GA; Walsh M; Smith AM; Morris-Stiff G
J Gastrointest Surg; 2012 Jul; 16(7):1422-8. PubMed ID: 22370733
[TBL] [Abstract][Full Text] [Related]
37. Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial.
Jonasch E; McCutcheon IE; Gombos DS; Ahrar K; Perrier ND; Liu D; Robichaux CC; Villarreal MF; Weldon JA; Woodson AH; Pilie PG; Fuller GN; Waguespack SG; Matin SF
Lancet Oncol; 2018 Oct; 19(10):1351-1359. PubMed ID: 30236511
[TBL] [Abstract][Full Text] [Related]
38. Clear cell endocrine pancreatic tumor mimicking renal cell carcinoma: a distinctive neoplasm of von Hippel-Lindau disease.
Hoang MP; Hruban RH; Albores-Saavedra J
Am J Surg Pathol; 2001 May; 25(5):602-9. PubMed ID: 11342771
[TBL] [Abstract][Full Text] [Related]
39. Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients.
Speisky D; Duces A; Bièche I; Rebours V; Hammel P; Sauvanet A; Richard S; Bedossa P; Vidaud M; Murat A; Niccoli P; Scoazec JY; Ruszniewski P; Couvelard A;
Clin Cancer Res; 2012 May; 18(10):2838-49. PubMed ID: 22461457
[TBL] [Abstract][Full Text] [Related]
40. Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated Tumors.
Suárez C; Vieito M; Valdivia A; González M; Carles J
Med Sci (Basel); 2023 Jun; 11(3):. PubMed ID: 37489462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
